Cargando…

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction

BACKGROUND: The effect of implantable cardioverter-defibrillator (ICD) therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes is not fully elucidated. METHODS: We examined the effect of ICD therapy on sudden cardiac death, cardiovascular death and all-cause mortal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rørth, Rasmus, Dewan, Pooja, Kristensen, Søren Lund, Jhund, Pardeep S., Petrie, Mark C., Køber, Lars, McMurray, John J. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652172/ https://www.ncbi.nlm.nih.gov/pubmed/30689020 http://dx.doi.org/10.1007/s00392-019-01415-z

Ejemplares similares

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
por: Shen, Li, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis
por: Curtain, James P, et al.
Publicado: (2023)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study
por: Rørth, Rasmus, et al.
Publicado: (2018)

Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
por: Butt, Jawad H, et al.
Publicado: (2023)

Impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for implantable cardioverter defibrillators
por: Joshi, Subodh B, et al.
Publicado: (2011)

Magnetic Resonance Assessment of Ejection Fraction Versus Echocardiography for Cardioverter-Defibrillator Implantation Eligibility
por: Schiau, Călin, et al.
Publicado: (2021)

Selection of patients eligible for implantable cardioverter defibrillator: beyond left ventricular ejection fraction
por: Rizzello, Vittoria
Publicado: (2022)

Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer
por: Rørth, Rasmus, et al.
Publicado: (2021)

Publisher Correction to: Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
Publicado: (2020)

The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes
por: Rørth, Rasmus, et al.
Publicado: (2018)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation
por: Joshi, Subodh B, et al.
Publicado: (2012)

Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
por: Butt, Jawad H., et al.
Publicado: (2023)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction
por: Mooney, Leanne, et al.
Publicado: (2023)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation( )
por: Kondo, Toru, et al.
Publicado: (2022)

Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality
por: Schrage, Benedikt, et al.
Publicado: (2022)

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35%
por: Wasfy, Jason H, et al.
Publicado: (2023)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022)

Relationship between right and left ventricular function in candidates for implantable cardioverter defibrillator with low left ventricular ejection fraction
por: Jimenez-Juan, Laura, et al.
Publicado: (2017)

Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
por: Shen, Li, et al.
Publicado: (2020)

Deactivation of implantable cardioverter-defibrillators
por: Wan, Darryl, et al.
Publicado: (2021)

Implantation of Implantable Cardioverter Defibrillators in Kazakhstan
por: Begisbayev, Temirkhan, et al.
Publicado: (2022)

The subcutaneous implantable cardioverter-defibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication
por: Tan, Jian Liang, et al.
Publicado: (2022)

Mortality outcome and predictive risk factors for death in patients with heart failure and reduced ejection fraction who declined implantable cardioverter defibrillator implantation in Singapore
por: Khoo, Chun Yuan, et al.
Publicado: (2018)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF
por: Ehteshami‐Afshar, Solmaz, et al.
Publicado: (2021)

Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas
por: Dewan, Pooja, et al.
Publicado: (2018)

Subcutaneous implantable cardioverter-defibrillator placement in a patient with a preexisting transvenous implantable cardioverter-defibrillator
por: Jazayeri, Mohammad-Ali, et al.
Publicado: (2017)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers
por: Madelaire, Christian, et al.
Publicado: (2020)

Relation of multicenter automatic defibrillator implantation trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator
por: Uslu, Abdulkadir, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rd30fpv2h0ob81cdkuq0iiu8cf